GlassScriptPhysician profile
Richard Twoy
NPI 1174641526
$5,703.18
in general payments reported to CMS, 2019-2025
21 companies · $696 in 2025
The $696 reported for 2025 was more than what 99% of Licensed Practical Nurse providers received nationally (typical 2025 total: $38.94).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $931 · 2023: $1,922 · 2024: $1,562 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $680.77 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $659.65 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $492.47 | 2021-2023 | Nuzyra |
| Abbvie INC. | $489.44 | 2021-2023 | |
| Glaxosmithkline, LLC. | $480.41 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.58 | 2024-2025 | Xifaxan |
| Eisai INC. | $313.59 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $251.04 | 2023-2024 | Ingrezza |
| Gilead Sciences, INC. | $246.38 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.98 | 2025 | Caplyta |
| Fresenius Kabi USA, LLC | $215.12 | 2024-2025 | Smoflipid |
| Novo Nordisk INC | $214.12 | 2022-2023 | |
| Genentech USA, INC. | $148.12 | 2024 | Columvi, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $137.20 | 2024 | |
| Ibsa Pharma INC. | $124.98 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $121.83 | 2023 | Dexcom G7 Gss (161) |
| Karyopharm Therapeutics INC. | $121.70 | 2024 | Xpovio |
| Argenx US, INC. | $110.49 | 2023 | Vyvgart |
| Abbott Laboratories | $103.13 | 2023 | Freestyle Libre 3 |
| Biogen, INC. | $101.71 | 2024 | Tysabri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.47 | 2023 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Twoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.